Information swept through Russian social networks that supposedly doctors had already been officially warned about the cessation of the supply of foreign drugs for asthma, and that it was necessary to urgently purchase the appropriate drugs. True, within a few hours, the Moscow Health Department issued an official refutation, saying that everything was in order with the medicines:
“The Moscow Department of Health does not confirm the fact of receiving a letter with a request to purchase drugs with specific trade names, as well as sending such letters to medical organizations.
In medical organizations subordinate to the Moscow Department of Health, there are no problems with drugs for the treatment of asthma. To date, a sufficient supply of these drugs has been created in the capital to provide preferential categories of citizens.
As for the drug "Pulmicort", used through a nebulizer, generics are registered in the Russian Federation, approved for use in children aged 6 months and older. All of them have been purchased and are available in sufficient quantities.
Also, city polyclinics are provided in sufficient quantities with all the necessary vaccines. At the moment, the drug under the trade name Pentaxim (vaccine against diphtheria, tetanus, haemophilus influenzae, poliomyelitis and whooping cough) continues to be used for vaccination, the ROTA-V-Aid vaccine is supplied for vaccination against rotavirus infection, and for hepatitis A vaccination there is a domestic vaccine "Algavak M".
Nevertheless, the issue of drug shortages continues to worry Russians. In this regard, the economist Dmitry Prokofiev turned to Vitaly Polushkin, the deputy chief physician of one of the Moscow clinics, with him. Here is what he replied:
“Deficiency, both existing and expected, is diverse. At a minimum, two groups can be distinguished - an absolute shortage, when something is not available without clear prospects for reproduction in Russia, and a relative one, when there is something, but it is difficult to get to it, and a relative one, when there is a drug globally, but it is difficult to use it. Consider the most likely options.
Calculating the quantitative effects of such a deficit is now an almost unrealistic task for those analytical centers that are available to the authorities and society.
But it is clear that with small individual values in each option, the synergistic effect of such a sharply reduced availability of drug care will worsen public health outcomes and significantly increase costs, especially for the elderly”.